Intra-articular lidocaine versus intravenous sedation for closed reduction of acute anterior shoulder dislocation in the emergency department: a systematic review and meta-analysis.

OBJECTIVE: Anterior shoulder dislocations are commonly treated in the emergency department (ED). Analgesia for reduction is provided by intra-articular lidocaine (IAL) injection or intravenous sedation (IV sedation). The objective of this systematic review and meta-analysis was to compare IAL versus IV sedation for closed reduction of acute anterior shoulder dislocation in the ED.
METHODS: Electronic searches of MEDLINE and EMBASE (1946-September 2021) were completed and reference lists were hand-searched. Randomized controlled trials (RCTs) comparing IAL and IV sedation for reduction of acute anterior shoulder dislocations among patients ≥ 15 years old in the ED were included. Outcomes of interest included a successful reduction, adverse events, ED length of stay, pain scores, procedure time, ease of reduction, patient satisfaction, and cost. Two reviewers independently screened abstracts, assessed study quality and extracted data. Data were pooled using random-effects models and reported as mean differences and risk ratios (RR) with 95% confidence intervals (CIs).
RESULTS: 12 RCTs were included with a total of 630 patients (IAL = 327; IV sedation = 303). There was no difference in reduction success between IAL and IV sedation (RR 0.93; 95% CI 0.86-1.01, I2 = 69%), significantly lower adverse events with IAL (RR 0.16; 95% CI 0.07-0.33, I2 = 0%), shorter ED length of stay with IAL (mean difference - 1.48; 95% CI - 2.48 to - 0.47, I2 = 93%), no difference in pain scores post-analgesia and no difference in ease of reduction.
CONCLUSIONS: Intra-articular lidocaine may have similar effectiveness as IV sedation in the successful reduction of anterior shoulder dislocations in the ED with fewer adverse events, shorter ED length of stay, and no difference in pain scores or ease of reduction. Intra-articular lidocaine may be an effective alternative to IV sedation for reducing anterior shoulder dislocations, particularly when IV sedation is contraindicated or not feasible.

Clinician’s Capsule

Introduction

Anterior shoulder dislocations represent 95% of all shoulder dislocations, and is the most common type of joint dislocation seen in the emergency department (ED) [1, 2]. Treatment of anterior shoulder dislocations involves relocating the humeral head within the glenoid fossa, using one of several previously described reduction techniques [3-6]. Imperative to the success of reduction is muscle relaxation and patient cooperation [2]. As such, analgesia is often required.

Intra-articular lidocaine and intravenous sedation (IV sedation) are two types of analgesia for anterior shoulder dislocation reduction [2]. There have been several randomized controlled trials (RCTs) comparing these two methods in the ED setting [7-14]. Despite the popularity of IV sedation, intra-articular lidocaine has been shown to have similar rates of successful reduction with fewer systemic complications and decreased costs [15]. In a 2014 systematic review and meta-analysis by Jiang et al., intra-articular lidocaine was found to be similar in reduction efficacy compared to IV sedation with an improved safety profile [16], despite the inclusion of a trial reporting a lower rate of successful reduction and decreased patient satisfaction with intra-articular lidocaine [17]. Additionally, the American College of Emergency Physicians have a toolkit entitled, ‘Managing Acute Pain’ which suggests intra-articular lidocaine may be equivalent to IV sedation for successful reduction of acute anterior shoulder dislocations [18].

Recently, three new trials were published comparing intra-articular lidocaine and IV sedation [19-21]. The primary objective of this systematic review and meta-analysis was to compare the efficacy of intra-articular lidocaine and IV sedation for successful closed reduction of acute anterior shoulder dislocation in the ED. Secondary outcomes of interest include adverse events, ED length of stay, change in pain scores, procedure time, ease of reduction, patient satisfaction, and cost.

Methods

Data sources and search strategy

In consultation with the review authors, a research librarian conducted the systematic literature searches in MEDLINE (1946–September 2021) using both Ovid and PubMed search interfaces, EMBASE (1947–September 2021), the Cochrane Central Register of Controlled Trials (September 2021), as well as electronic bibliographic databases. A comprehensive search strategy (see supplementary material for search strategy) included a combination of medical subject headings (MeSH) and free-text terms using various spelling and endings of key words. The protocol for this systematic review and meta-analysis was not registered online.

Eligibility criteria and study selection

RCTs published comparing the use of intra-articular lidocaine versus IV sedation (any agent) for the closed reduction of acute anterior shoulder dislocations among patients ≥ 15 years of age in the ED were eligible for inclusion. Studies involving only pediatric populations, posterior shoulder dislocations, fracture-dislocations, or settings other than the ED were excluded. Two reviewers independently screened the search output to identify potentially eligible trials. Corresponding full texts were then retrieved and assessed for inclusion. In the event of discrepancies, a third researcher adjudicated the decision. Reference lists of relevant articles and the regulatory website ‘clinicaltrials.gov’ were searched to identify any unpublished or missed RCTs.

Outcome measures

A standardized data collection form was used to extract data on patient demographics (country of study, sample size, patient age), intervention (intra-articular lidocaine versus IV sedation agents, concentrations, and doses if available) and outcomes. Data for each study was extracted by one researcher and verified by a second researcher. In the event of discrepancies, a third researcher adjudicated the decision. Outcomes of interest included a successful reduction, adverse events, ED length of stay, pain scores, procedure time, ease of reduction, patient satisfaction, and cost. We defined a successful reduction as post-reduction radiological confirmation of shoulder relocation. Monitored adverse events varied across trials, and for meta-analysis we included the presence or absence of adverse events as dictated by the individual RCTs. Pain differences were calculated from raw pain scores to provide pain reduction scores for meta-analysis. Pain scores were included if patient-reported pain was described on a 10-point scale. Procedure time was defined as the time for reduction, not the administration of anesthesia or length of stay post-reduction. Cost data were summarized narratively. Where raw data were required for meta-analyses and not derivable or reported, the authors were contacted in efforts to obtain this data.

Risk of bias assessment

Risk of bias for each individual trial was independently assessed by two reviewers using the Cochrane Collaboration’s tool for assessing risk of bias for systematic reviews of interventions [22]. We assessed the risk of bias for each study using the following domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. Each domain was assessed as having a low, unclear, or high risk of bias. Discrepancies were resolved by discussion and consensus amongst the authors.

Data synthesis and analysis

Direct comparisons of ED length of stay (in hours), pain score after anesthesia and before reduction, reduction in pain score, and procedure time (in minutes) were performed using inverse variance random-effects models to account for both within study and between study heterogeneity, and reported as mean differences with 95% confidence intervals (CIs) using Review Manager 5.3.4 (Nordic Cochrane Centre, Copenhagen, Denmark). A mean difference < 0 favored intra-articular lidocaine and statistical significance was achieved if the 95% CI of the pooled estimate excluded zero. Direct comparisons of dichotomous outcomes (successful reduction, patient satisfaction, adverse events, and provider ease of reduction) were performed using Mantel–Haenszel random-effects models and reported as risk ratios (RR) with 95% CIs. RRs > 1 favored intra-articular lidocaine, and statistical significance was achieved if the 95% CI of the pooled RR excluded unity. Statistical heterogeneity between studies was assessed using the I2 statistic, with I2 values ≥ 50% indicating substantial heterogeneity. We also conducted a subgroup analysis separating studies comparing meperidine/pethidine to intra-articular lidocaine as this drug is no longer used.

We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach which provides a structured and transparent framework to assess quality (high, moderate, low and very low) of the evidence [23]. We used conventional GRADE guidance and considered risk of bias, inconsistency, imprecision, indirectness, and publication bias for the body of evidence informing each outcome.

Results

Study selection and characteristics

The search strategy yielded 554 citations. After eliminating duplicates and screening studies that did not meet eligibility criteria, 23 studies remained for full-text review (Fig. 1). A total of 12 RCTs were included with a total of 630 patients (327 patients in the intra-articular lidocaine group and 303 patients in the IV sedation group) [8–14, 17, 19–21, 24]. A summary of trial characteristics is shown in Table 1. All studies were published between 1994 and 2020 involving ED populations from 6 countries and ages ranged from 16 to 89 years. One study was reported as an abstract, but additional data was obtained from the authors [20]. The intra-articular lidocaine group all received 1% lidocaine, with 2 trials administering 4 mg/kg and the remaining 10 trials administering 20 mL of lidocaine (regardless of body weight). The IV sedation groups across all trials received different medication combinations (anxiolytics, analgesics, or sedatives) and doses. Some trials had pre-determined medications and doses for IV sedation, while others were weight-based or up to the discretion of the treating physician. Risk of bias varied across trials (Table 2). All trials were found to have a low risk of bias regarding outcome data and reporting, and high risk of bias with regards to blinding of patients and providers.

Fig. 1

Flowchart of study eligibility

Table 1

Characteristics of included studies

Study	Country	Sample size	Patient age	Intervention	Outcomes	Successful reduction
Cheok 2011	Malaysia	N = 63 IAL = 32 IVS = 31	Mean = 32.4 Range = 16–82	IAL = 1% lidocaine 20 mL IVS = 1 mg/kg demerol and 0.1 mg/kg valium, titrated to patient response	Successful reduction Adverse events ED length of stay Pain score Ease of reduction Patient satisfaction Cost	IAL: 26/32 (81.3%) IVS: 31/31 (100%)
Hames 2011	Canada	N = 44 IAL = 25 IVS = 19	Median = 27 IQR = 21–54	IAL = 1% lidocaine 4 mg/kg (up to 200 mg) IVS = physician discretion (propofol alone or in combination with fentanyl or ketamine)	Successful reduction Adverse events ED length of stay Ease of reduction Patient satisfaction	IAL: 12/25: (48.0%) IVS: 19/19 (100%)
Kashani 2016	Iran	N = 104 IAL = 52 IVS = 52	Mean = 28.7 SD = 7.2 Range = 18–40	IAL = 1% lidocaine 20 mL IVS = 0.05 mg/kg midazolam and 1 μg/kg fentanyl	Successful reduction Adverse events ED length of stay Pain score Patient satisfaction	IAL: 51/52 (98.1%) IVS: 46/52 (88.5%)
Koneri 2020	United States	N = 43 IAL = 23 IVS = 20	Range = 18–70	IAL = 1% lidocaine 20 mL IVS = provider discretion (propofol or etomidate)	Successful reduction ED length of stay Patient satisfaction	IAL: 20/23 (87.0%) IVS: 20/20 (100%)
Kosnik 1999	United States	N = 49 IAL = 29 IVS = 20	Mean = 41 SD = 19.1	IAL = 1% lidocaine, 4 mg/kg (max 200 mg) IVS = 10 mg morphine (up to 30 mg) and 5 mg diazepam (up to 20 mg)	Successful reduction Adverse events Pain score Ease of reduction	IAL: 25/29 (86.2%) IVS: 20/20 (100%)
Matthews 1995	United States	N = 30 IAL = 15 IVS = 15	Mean = 36.7 Range = 20–75	IAL = 1% lidocaine 20 mL IVS = 10 mg morphine and 2 mg midazolam	Successful reduction Adverse events ED length of stay Pain score Ease of reduction Cost	IAL: 14/15 (93.3%) IVS: 15/15 (100%)
Miller 2002	United States	N = 30 IAL = 16 IVS = 14	Mean = 33.9 Range = 17–69	IAL = 1% lidocaine 20 mL IVS = 100mcg fentanyl and 2 mg midazolam	Successful reduction Adverse events ED length of stay Pain score Procedure time Cost	IAL: 16/16 (100%) IVS: 14/14 (100%)
Moharari 2008	Iran	N = 48 IAL = 24 IVS = 24	Mean = 35.3 SD = 13.18	IAL = 1% lidocaine 20 mL IVS = 25 mg meperidine and 5 mg diazepam	Successful reduction Adverse events ED length of stay Pain score Procedure time	IAL: 24/24 (100%) IVS: 24/24 (100%)
Orlinsky 2002	United States	N = 54 IAL = 29 IVS = 25	Mean = 37.4 SD = 16.4 Range = 18–80	IAL = 1% lidocaine 20 mL IVS = 1–2 mg/kg meperidine and 5-10 mg diazepam	Successful reduction Adverse events Ease of reduction Patient satisfaction Recovery time	IAL: 16/29 (55.2%) IVS: 11/25 (44.0%)
Pradhan 2006	Nepal	N = 45 IAL = 23 IVS = 22	Mean = 27.2 Range = 19–55	IAL = 1% lidocaine 20 mL IVS = 0.5 – 1.0 mg/kg propofol supplemented by pethidine	Successful reduction Adverse events Procedure time Ease of reduction Cost	IAL: 20/23 (87.0%) IVS: 22/22 (100%)
Suder 1994	Denmark	N = 68 IAL = 33 IVS = 35	Mean = 48 Range = 15–79	IAL = 1% lidocaine 20 mL IVS = pethidine or diazepam	Successful reduction Adverse events Pain score Procedure time Patient satisfaction	IAL: 32/33 (97.0%) IVS: 33/35 (94.3%)
Suder 1995	Denmark	N = 52 IAL = 26 IVS = 26	Mean = 47 Range = 18–89	IAL = 1% lidocaine, 20 mL IVS = pethidine/diazepam ‘sufficient dose’	Successful reduction Adverse events Pain score Procedure time Patient satisfaction	IAL: 18/26 (69.2%) IVS: 22/26 (84.6%)

IAL intraarticular lidocaine, IVS intravenous sedation, ED emergency department, IQR interquartile range, SD standard deviation

Table 2

Risk of bias summary for included trials

Trial	Random sequence generation	Allocation concealment	Blinding of patients/personnel	Blinding of outcome assessment	Incomplete outcome data	Selective outcome reporting	Other Bias
Cheok 2011	UNCLEARa	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	LOW
Hames 2011	LOW	LOW	HIGHd	UNCLEARa	LOW	LOW	HIGHe
Kashani 2016	LOW	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	LOW
Koneri 2020	UNCLEARb	UNCLEARb	HIGHd	UNCLEARb	LOWb	UNCLEARb	HIGHe
Kosnik 1999	LOW	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	HIGHe
Matthews 1995	LOW	LOW	HIGHd	UNCLEARa	LOW	LOW	UNCLEARf
Miller 2002	HIGHc	HIGHc	HIGHd	UNCLEARa	LOW	LOW	LOW
Moharari 2008	LOW	LOW	HIGHd	LOW	LOW	LOW	LOW
Pradhan 2006	UNCLEARa	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	HIGHf,g
Orlinsky 2002	LOW	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	HIGHe
Suder 1994	LOW	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	UNCLEARf
Suder 1995	LOW	UNCLEARa	HIGHd	UNCLEARa	LOW	LOW	UNCLEARf

aNo information provided

bData reported in abstract form only

cPatients were randomized based on odd vs even medical record numbers

dHealthcare providers and patients were not blind to the intervention

eInsufficient enrollment (underpowered) to meet the required sample size

fNo power calculation or sample size estimate provided

gProcedure time included mandatory 15 min wait for IAL group

Outcomes

Successful reduction

All 12 studies, with a total of 630 patients (327 patients in the intra-articular lidocaine group and 303 patients in the IV sedation group) reported on reduction success (Fig. 2) [8–14, 17, 19–21, 24]. The pooled estimate showed no difference in reduction success between intra-articular lidocaine and IV sedation (83.8% vs. 91.4%; RR 0.93; 95% CI 0.86–1.01, I2 = 69%, low certainty). The low certainty in evidence on GRADE assessment was a result of inconsistency across trials and non-blinding (Table 3). The subgroup analysis (supplementary Fig. 1) removing studies comparing meperidine/pethidine to intra-articular lidocaine did not a significant change in reduction success (intra-articular lidocaine: 83.8% vs. IV sedation without meperidine/pethidine 95.7%; RR 0.91; 95% CI 0.78–1.05, I2 = 80%).

Fig. 2

Direct comparison of successful reduction between IAL and IVS

Table 3

Summary of findings and GRADE assessment for the comparison of intraarticular lidocaine and intravenous sedation for acute anterior shoulder dislocation in the ED

Outcome	No. of studies	Certainty assessment					No. of patients		Effect		GRADE assessment
		Risk of bias	Inconsistency	Indirectness	Imprecision	Other	IAL	IVS	Relative (95% CI)	Absolute (95% CI)	Certainty	Importance
ED length of stay (h)	7	Seriousa	Not serious	Not serious	Not serious	None	155	144	–	MD 1.48 lower (2.48 lower to 0.47 lower)	⨁⨁⨁◯ MODERATE	IMPORTANT
Successful reduction	12	Seriousa	Seriousb	Not serious	Not serious	None	274/327 (83.8%)	277/303 (91.4%)	RR 0.93 (0.86–1.01)	64 fewer per 1000 (from 128 fewer to 9 more)	⨁⨁◯◯ LOW	IMPORTANT
Patient satisfaction	6	Seriousa	Seriousa	Not serious	Not serious	None	136/193 (70.5%)	169/187 (90.4%)	RR 0.80 (0.67–0.95)	181 fewer per 1000 (from 298 to 45 fewer)	⨁⨁⨁◯ MODERATE	IMPORTANT
Adverse events	11	Seriousa	Seriousa	Not serious	Not serious	None	4/303 (1.3%)	59/283 (20.8%)	RR 0.16 (0.07–0.33)	175 fewer per 1000 (from 194 to 140 fewer)	⨁⨁⨁◯ MODERATE	IMPORTANT
Pain scores	8	Seriousa	Seriousb	Not serious	Seriousc	None	227	217	–	MD 0.04 lower (1.1 lower to 1.02 higher)	⨁◯◯◯ VERY LOW	IMPORTANT
Reduction in pain score	4	Seriousa	Not serious	Not serious	Seriousd	None	131	132	–	MD 0.29 lower (1.08 lower to 0.5 higher)	⨁⨁◯◯ LOW	IMPORTANT
Procedure time	5	Seriousa	Not serious	Not serious	Not serious	None	122	121	–	MD 8 higher (4.42 higher to 11.57 higher)	⨁⨁⨁◯ MODERATE	IMPORTANT
Ease of reduction	5	Seriousa	Seriousb	Not serious	Seriousd	None	67/123 (54.5%)	79/110 (71.8%)	RR 0.78 (0.59–1.04)	158 fewer per 1000 (from 294 fewer to 29 more)	⨁◯◯◯ VERY LOW	IMPORTANT

IAL intraarticular lidocaine, IVS intravenous sedation, ED emergency department, CI confidence interval, RR relative risk, MD mean difference

aHealthcare providers and patients were not blind to the intervention

bResults inconsistent across trials

cThe 95% CI includes both a reduction and increase in pain scores

dSerious imprecision in the results

⨁⨁⨁◯

⨁⨁◯◯

⨁⨁⨁◯

⨁⨁⨁◯

⨁◯◯◯

⨁⨁◯◯

⨁⨁⨁◯

⨁◯◯◯

Adverse events

Eleven studies, with a total of 586 patients reported adverse events (Supplementary Fig. 2) [8–14, 17, 19, 21, 24]. The pooled estimate showed a difference in adverse events, with fewer occurring in the intra-articular lidocaine group compared to the IV sedation group (1.3% vs. 20.8%; RR 0.16; 95% CI 0.07–0.33, I2 = 0, moderate certainty). Two studies reported an adverse event in the intra-articular lidocaine groups, which included agitation and drowsiness. Adverse events reported in the IV sedation groups ranged from: respiratory depression (including apnea/hypoxia), hypotension, nausea/vomiting, headache, allergic reaction, and thrombophlebitis.

ED length of stay

Seven studies, with a total of 299 patients reported on ED length of stay (Supplementary Fig. 3) [8, 9, 11, 12, 17, 20, 24]. The pooled estimate showed a significant difference in mean ED length of stay with a shorter duration in the intra-articular lidocaine group compared to the IV sedation group (mean difference = − 1.48 h; 95% CI − 2.48 to − 0.47, I2 = 93%, moderate certainty).

Pain scores

Eight studies, with a total of 444 reported on pain scores after anesthesia and before reduction (Supplementary Fig. 4) [9–14, 19, 24]. The pooled estimate showed no difference in pain score after anesthesia and before reduction in the intra-articular lidocaine group compared to the IV sedation group (mean difference = − 0.04; 95% CI − 1.10 to 1.02, I2 = 96%, very low certainty). Four studies, with a total of 263 patients reported on the change in pain scores pre-anesthesia and post-reduction (Supplementary Fig. 5) [8, 9, 19, 24]. The pooled estimate showed no difference in the change in pain scores pre-anesthesia and post-reduction in the intra-articular lidocaine group compared to the IV sedation group (mean difference = − 0.29; 95% CI − 1.08 to 0.5, I2 = 0%, low certainty).

Procedural time

Five studies, with a total of 243 patients reported on the length of procedural time for reduction to occur (Supplementary Fig. 6) [9–11, 13, 21]. The pooled estimate showed a significant difference with increased procedural time in the intra-articular lidocaine group compared to IV sedation (mean difference = 8 min; 95% CI 4.42–11.57, I2 = 97%, moderate certainty).

Ease of reduction

Five studies, with a total of 233 patients reported on provider ease of reduction (Supplementary Fig. 7) [8, 12, 17, 21, 24]. The pooled estimate showed no statistically significant difference in ease of reduction in the intra-articular lidocaine group compared to IV sedation (54.5% vs. 71.8%; RR 0.78; 95% CI 0.59–1.04, I2 = 51%, very low certainty). The very low certainty in evidence on GRADE assessment for pain scores and ease of reduction was a result of inconsistency, imprecision, and non-blinding (Table 3).

Patient satisfaction

Six studies, with a total of 380 patients reported on patient satisfaction (Supplementary Fig. 8) [8, 10, 13, 17, 19, 24]. The pooled estimate showed a significant difference with decreased patient satisfaction in the intra-articular lidocaine group compared to IV sedation (70.5% vs. 90.4%; RR 0.80; 95% CI 0.67–0.95, I2 = 71%, moderate certainty).

Cost

The cost of intra-articular lidocaine was reported as less than IV sedation in four trials: $0.52 United States Dollars (USD) versus $97.64 USD [11], $117–$133 USD versus $159.55–$240.55 USD [12], 150 Nepalese Rupees (NPR) versus 400 NPR [21], and $10 USD versus $31 USD [24].

Discussion

In this systematic review and meta-analysis including 12 studies, with a total of 630 patients (327 patients in the intra-articular lidocaine and 303 patients in the IV sedation group), we found intra-articular lidocaine may have similar effectiveness as IV sedation in the successful reduction of anterior shoulder dislocations in the ED with fewer adverse events, shorter ED length of stay, and no difference in pain scores or ease of reduction. However, patient satisfaction was lower with intra-articular lidocaine.

Our findings were in agreement with previous systematic reviews, demonstrating the benefits of intra-articular lidocaine [16, 26–29]. In a 2011 systematic review and meta-analysis by Wakai et al., comparing the clinical efficacy and safety of intra-articular lignocaine and intravenous analgesia (with or without sedation) for reduction of acute anterior shoulder dislocation, there was no significant difference between intra-articular lidocaine and IV sedation with regard to the immediate success rate of reduction, pain during reduction, post-reduction pain relief and reduction failure [27]. Similar to our findings, the authors suggested intra-articular lidocaine may be less expensive and may be associated with fewer adverse effects and a shorter recovery time, compared to IV sedation. More recently, Jiang et al., included data from nine RCTs with a total of 438 patients and found intra-articular lidocaine may be safer than IV sedation as there were fewer complications with intra-articular lidocaine. Both techniques were similarly effective for manual closed reduction of acute anterior shoulder dislocation [28].

Strengths and limitations

Strengths of this review include explicit eligibility criteria, a comprehensive search, and independent duplicate assessment of eligibility. This is the most up to date systematic review and meta-analysis on this topic, and we used the GRADE approach which provides a structured and transparent framework to assess quality of the evidence [23].

This systematic review and meta-analysis has several limitations. As with all meta‐analyses, the results from this study are limited by the quality of trials included. One included trial was an abstract [20] that was unlikely to be peer reviewed to the same level of scrutiny as the full‐text journal articles. However, this was highlighted through our assessments showing high or unclear risks of bias in study methodology, varying or unclear definitions of outcomes, and how they were measured. We did not search grey literature for potential studies. However, we would suspect that the majority of RCTs would also be published and found in the databases searched. Many of the outcomes we assessed in the meta-analysis had a high I2 values, including the success of reduction, indicating significant heterogeneity between studies, which may in turn limit the application of our results. Furthermore, four outcomes (successful reduction, both pain score outcomes, and ease of reduction) had a low to very low certainty of evidence. Another limitation was the inconsistency in the type of IV sedation agents used both within and between trials. Six trials used meperidine/pethidine (Demerol) in combination with a benzodiazepine or propofol [8–10, 13, 21, 24]. The remaining six trials used propofol, etomidate, ketamine, morphine, fentanyl, midazolam and diazepam [11, 12, 14, 17, 19, 20]. Given the different mechanisms of action, this could influence potential adverse events and subsequent risk of occurrence. Finally, the success of intra-articular lidocaine may be influenced by provider skill, and most trials did not comment on physician comfort with shoulder joint injections [25].

Clinical implications

Intra-articular lidocaine and IV sedation have different advantages based on the ED setting in which a physician is working and are both useful skills for emergency medicine providers. Our findings suggest that IV sedation is associated with improved patient satisfaction and reduced procedural time. IV sedation may be the preferred option in a well-resourced setting when treating a patient who has previously had a difficult reduction, has significant apprehension to being alert during the procedure, has local anesthetic allergy or toxicity risk, or when the provider has discomfort with joint injection technique. Although intra-articular lidocaine may be associated with less patient satisfaction, intra-articular lidocaine may be beneficial to consider in several settings, including in low-resourced settings (e.g., single coverage EDs or remote communities) where access to IV sedation drugs or equipment may be limited or not feasible [29]. Additionally, in EDs where healthcare dollars are limited (e.g., low-income communities/countries, patients who must pay for treatment out of pocket), intra-articular lidocaine may offer similar clinical outcomes to IV sedation at a lower cost [30, 31]. In high volume EDs with bed shortages, intra-articular lidocaine may be considered advantageous for departmental flow given the decreased ED length of stay compared to IV sedation [32, 33]. Additionally, we found that there were fewer adverse events with intra-articular lidocaine compared to IV sedation. Commonly used IV sedation agents such as propofol and opioids, have several well-known side effects such as hypotension, apnea, nausea and vomiting [35, 36]. The most commonly reported adverse event from IV sedation in the included RCTs was respiratory depression [8–10, 13, 19, 24]. Given the potential adverse events associated with IV sedation, intra-articular lidocaine may be favorable in patients who are complex, clinically unstable, or thought to have predicted difficult airway. Also, due to the risk of apnea and respiratory depression, many EDs require a respiratory therapist or additional physician for procedural sedation. This this can be strenuous on busy or solo-coverage EDs. Bed shortages, resource scarcity, and precautions around potential aerosol generating medical procedures have been accentuated during the COVID-19 pandemic, further providing settings where intra-articular lidocaine may be considered alongside IV sedation [33, 34, 37].

Conclusions

In this systematic review and meta-analysis of 12 RCTs with 630 patients, we found that intra-articular lidocaine may have similar effectiveness as IV sedation in the successful reduction of anterior shoulder dislocations in the ED with fewer adverse events, shorter ED length of stay, and no difference in pain scores or ease of reduction. Intra-articular lidocaine may be an effective alternative to IV sedation for reducing anterior shoulder dislocations, particularly when IV sedation is contraindicated or not feasible.

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 18 KB)

Supplementary file2 (DOCX 107 KB)

What is known about the topic?

Several randomized controlled trials have compared intra-articular lidocaine (IAL) and intravenous sedation (IV sedation) for anterior shoulder dislocation reductions.

What did this study ask?

What is the effectiveness of IAL versus IV sedation on closed reduction of acute anterior shoulder dislocation in the ED?

What did this study find?

IAL had similar reduction success and pain scores as IV sedation, with fewer adverse events and shorter length of stay.

Why does this study matter to clinicians?

IAL may be an effective alternative for shoulder reduction when IV sedation is contraindicated or is not feasible (solo-coverage/low-resourced EDs).